3/15/2019 7:38:47 AM
Checkpoint Therapeutics FY Loss Attributable To Holders $36.4 Mln Or $1.27/Shr Vs Loss $22.7 Mln Or $1.00/Shr Last Year
11/2/2018 8:10:06 AM
Checkpoint Therapeutics Q3 Loss Attributable To Holders $9.3 Mln Or $0.32/Shr Vs Loss Of $5.9 Mln Or $0.26/Shr Last Year
10/16/2018 8:05:29 AM
Checkpoint Therapeutics Appoints Christian Béchon To Board Of Directors
9/25/2018 8:05:54 AM
Checkpoint Therapeutics Announces Presentation Of Updated Data From Phase 1/2 Trial Of EGFR Inhibitor CK-101
9/6/2018 7:32:48 AM
Checkpoint Therapeutics Says Encouraging Safety And Efficacy Data From Phase 1/2 Clinical Trial Of EGFR Inhibitor CK-101
8/13/2018 8:11:00 AM
Checkpoint Therapeutics Announces Clinical Data On EGFR Inhibitor CK-101 Selected For Late-Breaking Oral Presentation
4/18/2018 9:06:32 AM
Checkpoint Reports Preclinical Data On BET Inhibitor CK-103
3/21/2018 8:05:40 AM
Checkpoint Therapeutics Begins Dose Expansion Portion Of Phase 1 Trial Of Anti-PD-L1 Antibody CK-301
3/15/2018 7:35:01 AM
Checkpoint Therapeutics Announces Preclinical Data Presentation On Its BET Inhibitor CK-103 At AACR Meeting
3/8/2018 9:06:06 AM
Checkpoint Therapeutics Prices Public Offering Of 4.6 Mln Shares At $4.35/Shr